Linked Data API

Show Search Form

Search Results

1149774
star this property registered interest false more like this
star this property date less than 2019-10-14more like thismore than 2019-10-14
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Bevacizumab more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government whether Avastin has approval from the European Medicines Authority to be used to treat cancer. more like this
star this property tabling member printed
Lord Willis of Knaresborough remove filter
star this property uin HL67 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-10-25more like thismore than 2019-10-25
star this property answer text <p>Avastin has approval from the European Medicines Agency to be used to treat cancer in combination with specific chemotherapies in the advanced stages of several cancers. They are:</p><p>- Metastatic colorectal cancer;</p><p>- Metastatic breast cancer;</p><p>- Certain types of unresectable advanced, metastatic or recurrent lung cancer;</p><p>- Advanced or metastatic renal cell cancer;</p><p>- Advanced or recurrent or resistant ovarian/fallopian tube cancer; and</p><p>- Persistent or recurrent or metastatic cervical cancer.</p><p>Full details of the indications that Avastin is licensed for can be found in the European public assessment report for Avastin. It explains how the Agency assessed the medicine to recommend its authorisation and its conditions of use and is publicly available on their website.</p> more like this
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
less than 2019-10-25T12:00:04.5Zmore like thismore than 2019-10-25T12:00:04.5Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4151
star this property label Biography information for Lord Willis of Knaresborough more like this
1149777
star this property registered interest false more like this
star this property date less than 2019-10-14more like thismore than 2019-10-14
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cancer: Transplant Surgery more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government whether liver and bowel transplantation is currently approved by the National Institute for Health and Care Excellence for cancer patients; and if not, whether there are any clinical trials that have reached Phase 3. more like this
star this property tabling member printed
Lord Willis of Knaresborough remove filter
star this property uin HL70 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-10-25more like thismore than 2019-10-25
star this property answer text <p>The National Institute for Health and Care Excellence has not produced any guidance relating to combined liver and bowel transplants for cancer patients.</p><p>The Department funds research mainly through the National Institute for Health Research (NIHR). The usual practice of the NIHR and other research funders is not to ring-fence funds for expenditure on particular topics. The NIHR welcomes funding applications for research into any aspect of human health, including liver and bowel transplantation.</p><p>There has been one relevant clinical trial that reached Phase 3:</p><p>Study title: In open, prospective, single arm study investigating efficacy and safety of human hepatitis B immunoglobulin Zutectra in liver transplanted patients - the ZEUS Study.</p><p>Date: 22 November 2012 – 10 April 2014</p> more like this
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
less than 2019-10-25T11:56:33.353Zmore like thismore than 2019-10-25T11:56:33.353Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4151
star this property label Biography information for Lord Willis of Knaresborough more like this
1149775
star this property registered interest false more like this
star this property date less than 2019-10-14more like thismore than 2019-10-14
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Bevacizumab more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government whether there are (1) current applications, or (2) pending requests, for the use of Avastin following Phase 3 clinical trials. more like this
star this property tabling member printed
Lord Willis of Knaresborough remove filter
star this property uin HL68 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-10-25more like thismore than 2019-10-25
star this property answer text <p>To extend the indication of Avastin, the Marketing Authorisation Holder (Roche Registration GmbH) would need to submit the results of relevant clinical trials and other information to the European Medicines Agency (EMA) to demonstrate acceptable safety and efficacy and a positive balance of benefit to risk. At present, as Avastin has a European Community Marketing Authorisation, a national submission to the Medicines and Healthcare products Regulatory Agency to extend the indication is not possible.</p><p>There has not been any recent positive opinion from the EMA for a new indication of Avastin to be submitted to the European Commission and the EMA has not published any pending extension of indication applications.</p> more like this
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
less than 2019-10-25T12:11:29.293Zmore like thismore than 2019-10-25T12:11:29.293Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4151
star this property label Biography information for Lord Willis of Knaresborough more like this
1149773
star this property registered interest false more like this
star this property date less than 2019-10-14more like thismore than 2019-10-14
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Bevacizumab more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government why Avastin is not routinely made available on the NHS for certain groups of cancer patients. more like this
star this property tabling member printed
Lord Willis of Knaresborough remove filter
star this property uin HL66 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-10-25more like thismore than 2019-10-25
star this property answer text <p>Most new medicines are assessed by the National Institute for Health and Care Excellence (NICE) which makes recommendations for the National Health Service on whether they represent a clinically and cost effective use of NHS resources. Since 2016, NICE makes recommendations for the NHS on all new licensed cancer medicines through its technology appraisal programme. NHS commissioners are legally required to fund treatments recommended in NICE technology appraisal guidance.</p><p>NICE has appraised Avastin (bevacizumab) for use in the treatment of a number of different types of cancer and has unfortunately not been able to recommend it as a clinically and cost effective use of NHS resources for any type of cancer at the price offered by the drug company. Avastin is not therefore routinely funded by the NHS for any licensed indication.</p><p>Avastin is funded as an off-label treatment for some types of cancer through the Cancer Drugs Fund.</p> more like this
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
less than 2019-10-25T11:56:13.193Zmore like thisremove minimum value filter
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4151
star this property label Biography information for Lord Willis of Knaresborough more like this
1149776
star this property registered interest false more like this
star this property date less than 2019-10-14more like thismore than 2019-10-14
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Bevacizumab more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government, if Avastin is approved for safe use, whether it could be privately purchased for use by a patient being treated on the NHS. more like this
star this property tabling member printed
Lord Willis of Knaresborough remove filter
star this property uin HL69 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-10-28more like thismore than 2019-10-28
star this property answer text <p>For patients receiving private and National Health Service care for the same condition, NHS and private treatment can be supervised by one healthcare team. However, patients cannot choose to mix different parts of the same treatment between NHS and private care.</p><p>For example, a patient cannot have a cataract operation on the NHS and pay privately for special lens implants that are normally only available as part of private care.</p><p>Instead, a patient either has both the operation on the NHS and standard NHS lens implants or pay for both the operation and implants privately.</p> more like this
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
less than 2019-10-28T12:58:25.74Zmore like thismore than 2019-10-28T12:58:25.74Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4151
star this property label Biography information for Lord Willis of Knaresborough more like this